<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087722</url>
  </required_header>
  <id_info>
    <org_study_id>13-CC-8303</org_study_id>
    <nct_id>NCT02087722</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients</brief_title>
  <official_title>A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurim Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuhnil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy&#xD;
      to improve sleep quality in over 55 years old primary insomnia patients. This is a 2nd&#xD;
      bridging study to investigate the efficacy and safety of KI1001(Circadin®) in Korean&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted using a randomised, double-blind, placebo controlled parallel group&#xD;
      design, after a single-blind placebo period. Primary insomnia patients aged over 55 will be&#xD;
      screened for entry into the study.&#xD;
&#xD;
      After placebo run-in period, Patients will enter a 3 weeks double-blind treatment period.&#xD;
&#xD;
      Primary parameter is quality of sleep, secondary parameters are including getting to sleep,&#xD;
      awakening from sleep, behavior following wakefulness, quality of day and night, sleep latency&#xD;
      and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QOS in KMLSEQ</measure>
    <time_frame>Three weeks</time_frame>
    <description>KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire QOS - Quality of Sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GTS in KMLSEQ</measure>
    <time_frame>Three weeks</time_frame>
    <description>KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire GTS - Getting to Sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFS in KMLSEQ</measure>
    <time_frame>Three weeks</time_frame>
    <description>KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire AFS - Awakening from Sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BFW in LSEQ</measure>
    <time_frame>Three weeks</time_frame>
    <description>KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire BFW - Behavior following Wakefulness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOD</measure>
    <time_frame>Three weeks</time_frame>
    <description>Quality of Day in Patient Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QON</measure>
    <time_frame>Three weeks</time_frame>
    <description>Quality of Night in Patient Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>Three weeks</time_frame>
    <description>WHO-5 Wellbeing Index QOL - Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQI</measure>
    <time_frame>Three weeks</time_frame>
    <description>Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>KI1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KI1001</intervention_name>
    <arm_group_label>KI1001</arm_group_label>
    <other_name>Prolonged release melatonin 2mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablets 2mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female and aged ≥55 years&#xD;
&#xD;
          -  Suffering from primary insomnia according to DSM-IV criteria and for whom this is the&#xD;
             consultation complaint&#xD;
&#xD;
          -  Good anticipated compliance&#xD;
&#xD;
          -  Written informed consent to participate in the study given by the patient voluntarily&#xD;
&#xD;
          -  Confirmed diagnosis of primary insomnia by sleep history questionnaire Established&#xD;
             baseline pathology&#xD;
&#xD;
          -  A good compliance during the two-weeks placebo run-in period defined as 70% to 130% of&#xD;
             prescribed tablets&#xD;
&#xD;
          -  Correct use of the Sleep Diary and of the KMLSEQ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  According to DSM-IV, subjects belonging to the following groups are excluded :&#xD;
             780.59(breathing related sleep disorder); 307.45(circadian thyrhm sleep disorder);&#xD;
             307.47(dyssomnia not otherwise specified); 780.XX(sleep disorder due to a general&#xD;
             medical condition)&#xD;
&#xD;
          -  Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor&#xD;
             agonists&#xD;
&#xD;
          -  Known positive serology for human immunodeficiency virus (HIV) I antibodies or HIV II&#xD;
             antibodies&#xD;
&#xD;
          -  Known chronic active viral hepatitis&#xD;
&#xD;
          -  Drug abuse or history or drug abuse(including alcohol)&#xD;
&#xD;
          -  History of severe pathology likely to recur during or immediately after the study&#xD;
&#xD;
          -  History of severe cardiac disorders&#xD;
&#xD;
          -  History of severe neurological disorders or cerebral neurosurgery&#xD;
&#xD;
          -  History of severe psychiatric disorders, especially psychosis and depression,&#xD;
             sismotherapy&#xD;
&#xD;
          -  Depression will be assessed by the Raskin scale : a patient with a total score ≥ 6&#xD;
             will not be included&#xD;
&#xD;
          -  Anxiety will be assessed by the Covi scale : a patient with a total score ≥ 6 will not&#xD;
             be included&#xD;
&#xD;
          -  Dementia will be assessed with the Mini Mental State (MMS) : a patient with a score ≤&#xD;
             24 or 26 (depending on the socio-educational level of the patient) will not be&#xD;
             included&#xD;
&#xD;
          -  Neuro-psychiatric pathologies that might interfere with insomnia, patient assessment&#xD;
             or study medication&#xD;
&#xD;
          -  Use of psychotropic treatments for the past 3 months and during the study&#xD;
&#xD;
          -  Use of benzodiazepines or other hypnotics during preceding two weeks (including all&#xD;
             benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and&#xD;
             hydroxyzine)&#xD;
&#xD;
          -  All hypnotics or treatments used as an hypnotic are not allowed during the study&#xD;
&#xD;
          -  Severe pain likely to interfere with sleep&#xD;
&#xD;
          -  Other sleep disorders according to DSM-IV criteria identified by numerical ICD 9 code:&#xD;
             breathing-related sleep disorder (780.59), circadian rhythm sleep disorder (307.45),&#xD;
             dyssomnia not otherwise specified (307.47) and other sleep disorders (780.xx)&#xD;
&#xD;
          -  Serious diseases that could interfere with patient assessment&#xD;
&#xD;
          -  Organic pathologies which have not stabilised and that might interfere with sleep,&#xD;
             patient assessment or study medication&#xD;
&#xD;
          -  Intercurrent acute or chronic somatic diseases likely to interact with sleep (for&#xD;
             example: chronic pain from any aetiology, benign prostatic hypertrophy likely to&#xD;
             require surgery in the coming six months)&#xD;
&#xD;
          -  Any concomitant documented progressive disease likely to interfere with the conduct of&#xD;
             the study&#xD;
&#xD;
          -  Any medical condition which might interfere with the completion of the study, or which&#xD;
             would be adversely affected and thereby increasing the risk for the patient or&#xD;
             interfering with patient assessments.&#xD;
&#xD;
          -  Patients with an excessive consumption of alcohol, coffee or tea&#xD;
&#xD;
          -  Patients with an irregular lifestyle or life pattern (e.g. shift workers and patients&#xD;
             likely to be jet lagged)&#xD;
&#xD;
          -  Patients with a Body Mass Index above 30 - obesity&#xD;
&#xD;
          -  Patients who have taken any investigational drug within two months preceding the first&#xD;
             dose of the study drug. Investigational drug is defined as any drug for which a&#xD;
             marketing authorisation has not been granted in the country where the study was&#xD;
             conducted.&#xD;
&#xD;
          -  Patients receiving concomitant treatment which are not permitted&#xD;
&#xD;
          -  A positive drug screen (benzodiazepines and opiates) during the initial two week&#xD;
             placebo run-in period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Chul Hong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea, St. Vincent Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doo-Heum Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won-Chul Shin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyu-In Jung, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Korea Saint Paul's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

